

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	25.7	70.0	(41.5-110.7)	Male	9	14.0	64.5	(29.4-122.5)
Female	8	9.0	88.6	(38.1-174.5)	Female	11	10.8	102.0	(50.9-182.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.9	121.6	(44.4-264.7)	Male	2	3.8	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	8	2.9	272.1	(117.2-536.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	17	13.3	127.7	(74.4-204.5)
Female	96	94.3	101.8	(82.5-124.3)	Female	11	11.7	94.0	(46.9-168.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.1	nc	(nc-nc)	Male	7	9.8	71.4	(28.6-147.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	48	39.0	123.0	(90.7-163.1)	Female	9	9.9	90.6	(41.3-171.9)
Female	39	37.1	105.2	(74.8-143.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.4	nc	(nc-nc)
Male	7	6.4	109.4	(43.8-225.4)	Female	6	7.8	76.6	(28.0-166.8)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	103.1	96.0	(78.0-116.9)
Male	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.6	nc	(nc-nc)	Male	12	6.6	182.0	(93.9-317.9)
<u>Kidney & Renal Pelvis</u>					Female	3	3.9	nc	(nc-nc)
Male	5	10.7	46.7	(15.1-109.0)	<u>Testis</u>				
Female	6	6.6	90.5	(33.0-196.9)	Male	3	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	8	8.5	93.7	(40.3-184.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	8.1	61.6	(19.9-143.8)	Female	14	19.1	73.3	(40.1-123.0)
Female	11	6.6	167.0	(83.2-298.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	338	343.7	98.3	(88.1-109.4)
Male	1	5.0	nc	(nc-nc)	Female	332	314.0	105.7	(94.7-117.7)
Female	2	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	48.9	116.6	(88.3-151.1)					
Female	53	42.9	123.5	(92.5-161.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	57.7	83.2	(61.4-110.3)	Male	23	31.9	72.2	(45.7-108.3)
Female	18	22.3	80.7	(47.8-127.5)	Female	25	27.4	91.1	(59.0-134.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.4	96.7	(48.2-173.1)	Male	9	8.4	107.6	(49.1-204.2)
Female	10	10.2	98.1	(47.0-180.4)	Female	12	7.3	165.0	(85.2-288.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	1.8	277.8	(89.5-648.3)	Male	27	30.6	88.2	(58.1-128.4)
Female	222	224.6	98.9	(86.3-112.8)	Female	26	29.2	89.1	(58.2-130.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	10.2	68.6	(27.5-141.3)	Male	29	21.6	134.2	(89.9-192.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	71	87.3	81.3	(63.5-102.5)	Female	30	24.2	124.1	(83.7-177.2)
Female	106	91.9	115.4	(94.4-139.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	16.4	91.3	(51.0-150.5)
Male	13	14.2	91.5	(48.6-156.4)	Female	14	19.4	72.0	(39.3-120.8)
Female	5	4.4	113.5	(36.6-265.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	238	230.1	103.4	(90.7-117.5)
Male	3	6.0	nc	(nc-nc)	<u>Stomach</u>				
Female	4	5.1	nc	(nc-nc)	Male	14	14.8	94.8	(51.8-159.0)
<u>Kidney & Renal Pelvis</u>					Female	13	9.7	133.4	(71.0-228.1)
Male	11	23.7	46.5	(23.2-83.2)	<u>Testis</u>				
Female	10	16.2	61.9	(29.6-113.9)	Male	7	11.4	61.5	(24.7-126.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	9.9	110.9	(55.3-198.5)	Male	8	6.8	117.7	(50.7-231.9)
Female	3	2.9	nc	(nc-nc)	Female	17	22.5	75.6	(44.0-121.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	18.5	86.4	(49.4-140.4)	Female	47	45.7	102.8	(75.6-136.8)
Female	9	16.2	55.5	(25.3-105.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	745	775.3	96.1	(89.3-103.2)
Male	12	11.0	109.4	(56.5-191.1)	Female	767	768.8	99.8	(92.8-107.1)
Female	11	4.5	244.1	(121.7-436.8)					
<u>Lung and Bronchus</u>									
Male	107	109.4	97.8	(80.2-118.2)					
Female	100	105.6	94.7	(77.1-115.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.8	92.7	(44.4-170.5)	Male	5	5.7	87.0	(28.0-203.0)
Female	4	4.2	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.5	126.6	(50.7-260.8)
Female	23	41.1	56.0	(35.5-84.0)	Female	2	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.8	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	16.4	110.1	(65.2-174.0)	Female	3	4.4	nc	(nc-nc)
Female	14	17.5	79.9	(43.6-134.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.7	nc	(nc-nc)	Male	47	42.8	109.9	(80.7-146.1)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.4	nc	(nc-nc)	Female	10	8.3	121.2	(58.0-222.9)
Female	3	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	3	1.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	3	3.4	nc	(nc-nc)	Male	27	20.5	132.0	(87.0-192.1)
Female	2	3.0	nc	(nc-nc)	Female	16	19.6	81.7	(46.6-132.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	25.2	75.4	(45.4-117.8)	Male	18	12.9	139.5	(82.6-220.5)
Female	7	9.0	77.4	(31.0-159.5)	Female	6	10.5	57.4	(21.0-125.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.5	111.6	(36.0-260.5)	Male	2	3.6	nc	(nc-nc)
Female	5	4.0	125.0	(40.3-291.7)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	12.5	96.3	(49.7-168.2)
Female	93	91.8	101.4	(81.8-124.2)	Female	19	11.6	163.8	(98.6-255.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.9	154.3	(56.3-335.9)	Male	13	9.2	141.4	(75.2-241.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	49	37.9	129.4	(95.7-171.1)	Female	5	9.7	51.6	(16.6-120.3)
Female	32	36.7	87.2	(59.6-123.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	11	6.2	177.2	(88.3-317.0)	Male	135	102.3	131.9	(110.6-156.2)
Female	4	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	24	10.2	236.4	(151.4-351.7)	Female	24	18.9	127.3	(81.5-189.4)
Female	6	6.6	91.2	(33.3-198.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	5	4.3	115.4	(37.2-269.3)	Male	7	4.7	149.0	(59.7-306.9)
Female	2	1.2	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	12	7.6	157.0	(81.0-274.3)	Male	78	47.9	162.8	(128.6-203.1)
Female	6	6.4	94.2	(34.4-205.1)	Female	61	43.4	140.4	(107.4-180.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.3	95.1	(30.7-222.0)	Male	2	2.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	6	2.1	279.9	(102.2-609.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	15	18.3	82.0	(45.8-135.2)	Female	3	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	7.9	113.3	(51.7-215.1)	Female	1	1.9	nc	(nc-nc)
Female	10	6.9	143.9	(68.9-264.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	18	21.7	83.1	(49.2-131.4)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	0	2.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Male</u>				
Male	1	1.7	nc	(nc-nc)	Male	60	70.7	84.9	(64.8-109.3)
Female	0	1.3	nc	(nc-nc)	<u>Female</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	0	1.0	nc	(nc-nc)	Female	58	60.6	95.7	(72.6-123.7)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	10.1	nc	(nc-nc)					
Female	7	8.3	84.5	(33.8-174.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	5	3.0	166.8	(53.8-389.2)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.1	nc	(nc-nc)	7	11.2	62.3	(25.0-128.4)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>9</u>				
Male	0	0.3	nc	(nc-nc)	9	9.3	96.5	(44.1-183.3)	
Female	0	0.2	nc	(nc-nc)	<u>Female</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>9</u>				
Male	1	0.2	nc	(nc-nc)	<u>Female</u>				
Female	0	0.0	nc	(nc-nc)	<u>9</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	1	1.6	nc	(nc-nc)	7	11.2	62.3	(25.0-128.4)	
Female	0	1.3	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>9</u>				
Male	1	1.6	nc	(nc-nc)	<u>Female</u>				
Female	0	1.3	nc	(nc-nc)	<u>9</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.1	nc	(nc-nc)	5	8.4	59.3	(19.1-138.3)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					5				
Male	0	0.2	nc	(nc-nc)	6.7	74.6	(24.0-174.0)		
Female	0	0.1	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.1	nc	(nc-nc)	<u>Male</u>				
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	1	1.2	nc	(nc-nc)	<u>Female</u>				
Female	0	0.9	nc	(nc-nc)	<u>Male</u>				
					5				
					6.7				
					74.6				
					(24.0-174.0)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	35.9	122.6	(89.1-164.6)	Male	13	18.8	69.1	(36.8-118.2)
Female	19	15.5	122.9	(74.0-192.0)	Female	13	17.9	72.7	(38.7-124.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.4	93.2	(34.0-202.9)	Male	4	5.1	nc	(nc-nc)
Female	9	6.6	137.0	(62.5-260.1)	Female	3	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	18.2	82.4	(46.1-136.0)
Female	137	146.5	93.5	(78.5-110.6)	Female	21	19.8	106.1	(65.7-162.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.6	nc	(nc-nc)	Male	13	12.4	104.5	(55.6-178.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	44	53.6	82.1	(59.6-110.2)	Female	12	15.9	75.7	(39.1-132.2)
Female	52	64.5	80.6	(60.2-105.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.0	119.6	(61.7-209.0)
Male	10	8.5	117.3	(56.1-215.7)	Female	11	13.7	80.5	(40.1-144.0)
Female	5	3.1	163.1	(52.5-380.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	116	137.1	84.6	(69.9-101.5)
Male	3	3.1	nc	(nc-nc)	<u>Stomach</u>				
Female	6	3.0	200.5	(73.2-436.3)	Male	13	9.1	143.2	(76.2-244.9)
<u>Kidney & Renal Pelvis</u>					Female	7	6.9	100.8	(40.4-207.8)
Male	17	14.0	121.6	(70.8-194.7)	<u>Testis</u>				
Female	8	10.8	74.3	(32.0-146.4)	Male	5	6.1	81.7	(26.3-190.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.9	nc	(nc-nc)	Male	5	3.8	131.1	(42.3-306.0)
Female	5	1.9	267.7	(86.3-624.6)	Female	16	14.2	112.9	(64.5-183.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	11.0	nc	(nc-nc)	Female	34	29.3	115.9	(80.3-162.0)
Female	14	10.9	128.1	(70.0-214.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	438	465.7	94.0	(85.4-103.3)
Male	5	6.5	77.2	(24.9-180.3)	Female	484	513.9	94.2	(86.0-103.0)
Female	1	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	70	67.0	104.5	(81.5-132.0)					
Female	59	71.4	82.6	(62.9-106.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	16.0	106.3	(61.9-170.3)	Male	16	8.5	188.8	(107.8-306.6)
Female	2	5.3	nc	(nc-nc)	Female	9	6.6	136.4	(62.2-258.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	10	8.1	124.0	(59.3-228.0)
Female	65	59.9	108.6	(83.8-138.4)	Female	6	6.9	86.4	(31.5-188.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	24.3	86.4	(53.5-132.1)	Female	11	6.2	177.7	(88.6-318.0)
Female	20	21.4	93.6	(57.2-144.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.6	nc	(nc-nc)
Male	5	4.1	123.0	(39.6-287.1)	Female	4	4.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	67.0	117.9	(93.4-147.0)
Male	4	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.2	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	9	5.2	173.3	(79.1-328.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.9	101.3	(32.6-236.3)	Female	14	12.3	113.6	(62.1-190.7)
Female	4	3.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	208	215.8	96.4	(83.7-110.4)
Male	4	3.2	nc	(nc-nc)	Female	198	191.5	103.4	(89.5-118.8)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	31.0	38.7	(20.0-67.7)					
Female	21	26.1	80.5	(49.8-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	19.9	131.0	(85.5-191.9)	Male	12	10.1	118.7	(61.2-207.3)
Female	12	7.8	153.4	(79.2-268.0)	Female	1	8.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.8	101.6	(48.7-186.9)
Female	76	72.8	104.4	(82.3-130.7)	Female	9	9.9	91.2	(41.6-173.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	7	7.0	100.5	(40.2-207.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	29.8	70.5	(43.6-107.8)	Female	10	7.9	126.9	(60.7-233.4)
Female	37	33.0	112.1	(78.9-154.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.6	124.7	(50.0-257.0)
Male	5	4.7	105.4	(34.0-246.0)	Female	5	7.0	71.8	(23.1-167.5)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	76	75.4	100.8	(79.4-126.1)
Male	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.6	nc	(nc-nc)
Male	5	7.8	64.4	(20.8-150.3)	<u>Testis</u>				
Female	6	5.4	111.0	(40.5-241.6)	Male	3	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.3	152.9	(49.3-356.8)	Male	2	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	6.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.1	99.0	(36.1-215.4)	Female	15	14.6	102.6	(57.4-169.2)
Female	7	5.6	124.7	(50.0-257.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	252	255.5	98.6	(86.8-111.6)
Male	2	3.6	nc	(nc-nc)	Female	249	256.2	97.2	(85.5-110.0)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	36.9	122.1	(89.0-163.4)					
Female	22	35.7	61.6	(38.6-93.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	29.1	75.7	(47.4-114.6)	Male	28	15.3	183.5	(121.9-265.2)
Female	13	10.9	119.1	(63.3-203.7)	Female	20	13.0	153.6	(93.8-237.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.3	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.6	102.5	(57.3-169.1)
Female	129	113.2	114.0	(95.2-135.4)	Female	10	14.2	70.5	(33.7-129.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.8	nc	(nc-nc)	Male	14	11.1	126.4	(69.0-212.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	44.1	93.0	(66.7-126.1)	Female	9	12.1	74.5	(34.0-141.5)
Female	38	45.1	84.3	(59.6-115.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	8.4	nc	(nc-nc)
Male	4	7.3	nc	(nc-nc)	Female	13	9.5	136.8	(72.8-234.0)
Female	4	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	127	118.3	107.4	(89.5-127.8)
Male	6	2.1	289.7	(105.8-630.6)	<u>Stomach</u>				
Female	2	2.3	nc	(nc-nc)	Male	3	7.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	4.8	nc	(nc-nc)
Male	13	12.0	108.0	(57.4-184.7)	<u>Testis</u>				
Female	8	8.0	99.7	(42.9-196.5)	Male	0	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	5.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	10	10.3	97.0	(46.4-178.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.0	133.3	(68.8-232.8)	Female	17	23.1	73.7	(42.9-118.0)
Female	6	8.1	74.1	(27.1-161.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	346	387.1	89.4	(80.2-99.3)
Male	5	5.6	89.0	(28.7-207.7)	Female	341	379.8	89.8	(80.5-99.8)
Female	2	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	55.3	47.0	(30.7-68.9)					
Female	22	51.7	42.5	(26.6-64.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	16	15.7	101.8	(58.2-165.3)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.1	84.2	(30.7-183.2)	Female	0	1.7	nc	(nc-nc)
Female	7	6.2	112.6	(45.1-232.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	29	18.7	155.0	(103.8-222.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	1.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	9.0	67.0	(24.5-145.8)	Male	70	60.8	115.0	(89.7-145.4)
Female	10	7.6	132.1	(63.2-242.9)	Female	57	52.4	108.8	(82.4-141.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	Female	7	9.6	73.3	(29.4-151.0)
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	0	1.5	nc	(nc-nc)	Female	7	9.6	73.3	(29.4-151.0)
Female	1	1.1	nc	(nc-nc)	<u>Female</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.9	102.0	(32.9-238.1)	Male	6	2.5	240.4	(87.8-523.3)
Female	1	1.7	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	20	17.0	117.4	(71.7-181.4)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	7.3	68.1	(21.9-158.8)	Female	0	1.8	nc	(nc-nc)
Female	13	6.8	190.7	(101.5-326.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	18	19.1	94.3	(55.9-149.1)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.9	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	2	1.5	nc	(nc-nc)	Male	12	9.3	129.5	(66.8-226.2)
Female	0	1.2	nc	(nc-nc)	Female	6	8.1	74.2	(27.1-161.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.1	76.9	(30.8-158.5)	Male	2	5.0	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
Female	21	29.1	72.1	(44.6-110.3)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	13.7	65.5	(29.9-124.3)	Female	4	3.1	nc	(nc-nc)
Female	8	12.1	66.1	(28.4-130.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.6	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	34.9	103.1	(72.2-142.8)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.9	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	93	119.9	77.5	(62.6-95.0)
Male	0	1.7	nc	(nc-nc)	Female	75	98.8	75.9	(59.7-95.2)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	17.1	64.4	(32.1-115.3)					
Female	12	13.9	86.6	(44.7-151.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.6	92.9	(40.0-183.1)	Male	6	4.4	136.5	(49.8-297.1)
Female	9	3.3	275.6	(125.8-523.3)	Female	2	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.3	164.5	(65.9-338.9)
Female	25	31.5	79.4	(51.4-117.3)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	13.0	69.5	(31.7-131.9)	Female	2	3.4	nc	(nc-nc)
Female	14	13.6	102.7	(56.1-172.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	36	33.7	106.8	(74.8-147.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.4	nc	(nc-nc)	Female	5	6.4	78.1	(25.2-182.4)
Female	0	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	2	2.6	nc	(nc-nc)	Male	23	16.2	142.4	(90.2-213.7)
Female	2	2.3	nc	(nc-nc)	Female	24	15.2	158.2	(101.3-235.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	100.4	(32.4-234.4)	Male	1	2.5	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	9	20.4	44.1	(20.1-83.7)	Female	0	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	7.4	94.0	(37.7-193.7)	Female	0	2.3	nc	(nc-nc)
Female	9	10.5	85.6	(39.1-162.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	1.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	15	18.3	81.8	(45.7-134.9)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	4	1.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.5	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	54	62.5	86.4	(64.9-112.7)
Male	0	0.9	nc	(nc-nc)	Female	39	74.3	52.5	(37.3-71.8)
Female	1	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.8	79.1	(31.7-163.1)					
Female	5	10.0	49.9	(16.1-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.7	163.5	(59.7-355.8)	Male	2	2.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	5	1.8	278.9	(89.9-650.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	14	15.6	89.7	(49.0-150.6)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.8	103.3	(37.7-224.8)	Female	3	1.6	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	16.3	134.6	(84.3-203.7)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	53	53.3	99.4	(74.4-130.0)
Male	0	0.9	nc	(nc-nc)	Female	43	47.2	91.1	(65.9-122.7)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	7.2	110.5	(47.6-217.8)					
Female	6	5.9	100.9	(36.8-219.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	33.8	118.4	(84.6-161.3)	Male	14	17.4	80.3	(43.8-134.7)
Female	15	12.2	122.7	(68.6-202.5)	Female	15	13.9	107.5	(60.1-177.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.1	132.1	(56.9-260.3)	Male	3	4.8	nc	(nc-nc)
Female	1	5.4	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	9	16.9	53.4	(24.4-101.3)
Female	120	121.6	98.7	(81.8-118.0)	Female	14	15.7	89.2	(48.7-149.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.2	nc	(nc-nc)	Male	11	12.2	90.5	(45.1-162.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	50.7	84.9	(61.4-114.3)	Female	10	13.0	77.1	(36.9-141.9)
Female	43	50.3	85.6	(61.9-115.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	9.5	73.4	(29.4-151.1)
Male	10	8.2	121.7	(58.3-223.8)	Female	8	10.7	75.0	(32.3-147.7)
Female	6	2.4	249.0	(90.9-542.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	115	133.9	85.9	(70.9-103.1)
Male	3	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.2	nc	(nc-nc)	Male	10	8.5	117.2	(56.1-215.5)
<u>Kidney & Renal Pelvis</u>					Female	3	5.3	nc	(nc-nc)
Male	13	13.5	96.4	(51.3-164.8)	<u>Testis</u>				
Female	7	8.8	79.4	(31.8-163.5)	Male	5	4.4	113.4	(36.5-264.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	5.7	87.6	(28.2-204.5)	Male	2	3.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	10	10.7	93.2	(44.6-171.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	10.3	58.1	(21.2-126.4)	Female	27	24.8	108.9	(71.8-158.5)
Female	3	8.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	396	442.9	89.4	(80.8-98.7)
Male	6	6.3	95.6	(34.9-208.1)	Female	404	414.4	97.5	(88.2-107.5)
Female	5	2.4	204.8	(66.0-477.8)					
<u>Lung and Bronchus</u>									
Male	61	63.9	95.5	(73.0-122.7)					
Female	59	58.2	101.4	(77.2-130.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	5	7.2	69.8	(22.5-162.9)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	8.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	19	27.1	70.2	(42.3-109.7)
Male	0	0.4	nc	(nc-nc)	Female	20	23.2	86.1	(52.6-133.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	3.9	nc	(nc-nc)					
Female	6	3.3	184.5	(67.4-401.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	12	9.9	121.1	(62.5-211.5)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	16	10.0	160.4	(91.6-260.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	4.6	nc	(nc-nc)	Male	30	33.3	90.0	(60.7-128.5)
Female	4	3.8	nc	(nc-nc)	Female	29	30.1	96.3	(64.5-138.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.3	116.5	(70.1-181.9)	Male	11	9.4	116.6	(58.1-208.6)
Female	2	6.2	nc	(nc-nc)	Female	12	7.9	152.0	(78.4-265.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.9	89.6	(38.6-176.6)
Female	66	66.1	99.9	(77.3-127.1)	Female	7	8.2	85.3	(34.2-175.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	25.1	63.8	(36.5-103.7)	Female	8	7.0	114.6	(49.4-225.9)
Female	18	26.5	68.0	(40.3-107.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	4.1	nc	(nc-nc)	Male	57	63.7	89.4	(67.7-115.9)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.0	71.7	(23.1-167.3)	Female	13	12.8	101.5	(54.0-173.6)
Female	2	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	3	5.4	nc	(nc-nc)	Male	21	30.4	69.0	(42.7-105.5)
Female	2	4.8	nc	(nc-nc)	Female	29	28.3	102.4	(68.5-147.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	42.1	111.5	(81.9-148.3)	Male	19	22.5	84.5	(50.8-132.0)
Female	22	15.7	140.3	(87.9-212.5)	Female	18	18.6	96.8	(57.4-153.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	8.0	99.6	(42.9-196.3)	Male	8	6.1	131.3	(56.5-258.7)
Female	6	7.2	83.6	(30.5-181.9)	Female	1	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	24	21.7	110.5	(70.8-164.4)
Female	144	158.5	90.8	(76.6-106.9)	Female	26	20.4	127.6	(83.3-187.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.9	nc	(nc-nc)	Male	17	15.7	108.4	(63.1-173.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	68	63.8	106.6	(82.8-135.2)	Female	14	17.0	82.5	(45.0-138.4)
Female	67	65.1	102.9	(79.8-130.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	12.0	133.0	(76.0-216.0)
Male	12	10.3	116.3	(60.0-203.2)	Female	14	13.7	101.9	(55.7-170.9)
Female	5	3.1	160.9	(51.9-375.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	123	164.9	74.6	(62.0-89.0)
Male	0	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.2	nc	(nc-nc)	Male	8	10.8	74.4	(32.0-146.6)
<u>Kidney & Renal Pelvis</u>					Female	4	6.9	nc	(nc-nc)
Male	18	17.1	105.1	(62.2-166.1)	<u>Testis</u>				
Female	8	11.4	70.3	(30.3-138.5)	Male	4	6.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	7.2	69.7	(22.5-162.6)	Male	0	4.5	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	14	14.8	94.6	(51.7-158.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	13.3	67.5	(30.8-128.2)	Female	31	32.0	97.0	(65.9-137.7)
Female	8	11.5	69.5	(29.9-136.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	501	556.5	90.0	(82.3-98.3)
Male	5	8.0	62.6	(20.2-146.1)	Female	505	539.1	93.7	(85.7-102.2)
Female	1	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	80	79.3	100.9	(80.0-125.6)					
Female	69	74.0	93.3	(72.6-118.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.7	108.5	(62.0-176.2)	Male	8	9.8	81.5	(35.1-160.6)
Female	7	5.1	137.6	(55.1-283.5)	Female	15	8.2	182.0	(101.8-300.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	15	9.0	167.5	(93.7-276.2)
Female	86	68.3	125.9	(100.7-155.4)	Female	7	7.3	95.4	(38.2-196.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.5	nc	(nc-nc)	Male	1	7.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	23.5	140.2	(96.5-196.9)	Female	16	6.9	231.3	(132.1-375.6)
Female	21	20.8	101.2	(62.6-154.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	4.5	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	66.7	92.9	(71.2-119.1)
Male	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.2	nc	(nc-nc)
Male	10	7.4	134.5	(64.4-247.4)	<u>Testis</u>				
Female	1	4.3	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	9	7.7	116.9	(53.4-222.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	5.4	nc	(nc-nc)	Female	12	13.4	89.7	(46.3-156.7)
Female	5	4.3	115.5	(37.2-269.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	214	220.7	97.0	(84.4-110.9)
Male	1	3.5	nc	(nc-nc)	Female	244	207.7	117.4	(103.2-133.1)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	29.5	108.5	(74.2-153.1)					
Female	33	25.3	130.5	(89.8-183.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	10	5.7	174.5	(83.6-321.0)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	5	6.1	82.0	(26.4-191.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.3	nc	(nc-nc)	Male	19	19.8	95.8	(57.6-149.6)
Female	0	0.1	nc	(nc-nc)	Female	18	17.1	105.4	(62.4-166.6)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	2.7	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.8	132.4	(60.4-251.4)	Male	2	4.0	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	22	26.4	83.4	(52.2-126.2)	Female	0	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	10.6	179.6	(108.1-280.5)	Female	6	2.7	220.6	(80.6-480.2)
Female	6	8.9	67.1	(24.5-146.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	28.1	124.3	(86.6-172.9)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.7	nc	(nc-nc)	Male	6	1.1	570.0	(208.1-1240.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	9	5.2	171.7	(78.3-325.9)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	104	94.4	110.2	(90.1-133.5)
Male	0	1.5	nc	(nc-nc)	Female	76	83.1	91.5	(72.1-114.5)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	13.1	68.5	(31.3-130.1)					
Female	6	10.8	55.3	(20.2-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	16.1	68.5	(34.1-122.5)	Male	12	8.0	150.7	(77.8-263.3)
Female	2	5.1	nc	(nc-nc)	Female	11	5.8	190.1	(94.8-340.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	5	2.3	219.8	(70.8-513.0)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	7.7	168.9	(89.8-288.8)
Female	66	52.5	125.7	(97.2-159.9)	Female	4	6.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	1	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	24.1	91.2	(57.1-138.0)	Female	8	5.6	143.3	(61.7-282.4)
Female	13	21.3	60.9	(32.4-104.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.6	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	5	4.5	111.8	(36.0-260.9)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	77	64.0	120.3	(94.9-150.3)
Male	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.3	nc	(nc-nc)
Male	2	6.4	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.7	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	13	4.4	297.7	(158.3-509.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.7	126.5	(46.2-275.4)	Female	10	10.8	92.8	(44.4-170.6)
Female	7	3.7	189.1	(75.8-389.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	194	208.2	93.2	(80.5-107.3)
Male	5	3.0	168.3	(54.2-392.8)	Female	184	175.7	104.8	(90.2-121.0)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	30.0	33.4	(16.0-61.4)					
Female	15	23.9	62.9	(35.2-103.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	17.9	139.3	(90.1-205.6)	Male	9	9.6	93.5	(42.7-177.5)
Female	3	5.9	nc	(nc-nc)	Female	8	7.3	110.0	(47.4-216.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.2	109.2	(52.3-200.8)
Female	82	64.5	127.1	(101.1-157.8)	Female	6	7.7	77.7	(28.4-169.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.8	nc	(nc-nc)	Male	7	7.1	99.1	(39.7-204.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	27.4	84.0	(53.2-126.1)	Female	5	6.7	74.2	(23.9-173.1)
Female	18	23.8	75.7	(44.8-119.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.6	nc	(nc-nc)	Male	82	75.5	108.6	(86.4-134.8)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	7.6	144.9	(72.2-259.3)	Female	11	13.4	81.9	(40.8-146.5)
Female	4	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	3.2	nc	(nc-nc)	Male	12	5.5	218.9	(113.0-382.4)
Female	0	0.8	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	3.5	nc	(nc-nc)	Male	44	34.7	126.7	(92.0-170.1)
Female	1	1.2	nc	(nc-nc)	Female	28	29.1	96.3	(64.0-139.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	19.8	100.8	(61.6-155.7)	Male	7	9.6	72.6	(29.1-149.6)
Female	4	7.2	nc	(nc-nc)	Female	14	7.5	186.1	(101.6-312.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.3	183.2	(66.9-398.7)	Male	2	2.8	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.4	95.4	(43.5-181.1)
Female	79	68.1	116.0	(91.8-144.6)	Female	7	9.0	77.7	(31.1-160.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	8	6.8	118.5	(51.0-233.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	29.5	98.2	(65.7-141.0)	Female	5	7.3	68.4	(22.0-159.6)
Female	36	30.3	118.6	(83.1-164.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.6	nc	(nc-nc)
Male	0	4.7	nc	(nc-nc)	Female	12	6.4	187.8	(96.9-328.0)
Female	2	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	86	74.8	114.9	(91.9-141.9)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	5.0	99.0	(31.9-231.1)
<u>Kidney & Renal Pelvis</u>					Female	2	3.3	nc	(nc-nc)
Male	5	7.5	66.3	(21.4-154.8)	<u>Testis</u>				
Female	10	5.0	200.0	(95.7-367.8)	Male	5	1.8	273.1	(88.0-637.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	5.4	110.4	(40.3-240.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	5.9	136.4	(58.8-268.9)	Female	12	13.7	87.5	(45.1-152.8)
Female	7	5.1	136.7	(54.7-281.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	247	250.6	98.6	(86.6-111.6)
Male	3	3.5	nc	(nc-nc)	Female	260	236.4	110.0	(97.0-124.2)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	36.4	76.9	(51.1-111.2)					
Female	29	33.0	87.9	(58.9-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	86	59.4	144.9	(115.9-178.9)	Male	32	31.8	100.7	(68.9-142.2)
Female	18	23.7	76.0	(45.0-120.2)	Female	30	27.9	107.5	(72.5-153.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.1	89.8	(43.0-165.1)	Male	8	8.6	93.1	(40.1-183.5)
Female	11	10.6	104.3	(52.0-186.6)	Female	4	7.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	29	30.4	95.4	(63.9-137.0)
Female	255	240.3	106.1	(93.5-120.0)	Female	19	30.6	62.1	(37.4-97.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	10.5	47.7	(15.4-111.4)	Male	26	22.2	117.0	(76.4-171.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	98	89.7	109.2	(88.7-133.1)	Female	29	25.5	113.7	(76.1-163.3)
Female	81	96.9	83.6	(66.4-103.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	16.9	82.6	(45.1-138.7)
Male	16	14.7	108.5	(62.0-176.2)	Female	12	20.6	58.3	(30.1-101.9)
Female	2	4.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	186	241.8	76.9	(66.3-88.8)
Male	4	4.8	nc	(nc-nc)	<u>Stomach</u>				
Female	7	4.3	164.6	(66.0-339.2)	Male	13	15.0	86.6	(46.0-148.0)
<u>Kidney & Renal Pelvis</u>					Female	8	10.2	78.4	(33.8-154.6)
Male	35	24.5	142.6	(99.3-198.3)	<u>Testis</u>				
Female	25	17.2	145.1	(93.9-214.2)	Male	9	8.7	103.7	(47.3-197.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	10.3	87.1	(39.7-165.4)	Male	8	6.4	124.7	(53.7-245.7)
Female	3	3.1	nc	(nc-nc)	Female	31	21.9	141.5	(96.1-200.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	18.5	113.2	(70.1-173.1)	Female	43	48.9	88.0	(63.6-118.5)
Female	18	16.9	106.6	(63.1-168.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	826	794.9	103.9	(96.9-111.3)
Male	8	11.4	70.4	(30.3-138.7)	Female	804	811.8	99.0	(92.3-106.1)
Female	8	4.7	169.0	(72.8-332.9)					
<u>Lung and Bronchus</u>									
Male	142	113.9	124.7	(105.0-147.0)					
Female	140	113.2	123.7	(104.1-146.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.2	69.8	(22.5-162.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	2	3.4	nc	(nc-nc)	Male	18	24.2	74.4	(44.1-117.5)
Female	1	2.7	nc	(nc-nc)	Female	16	20.7	77.3	(44.2-125.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.1	125.8	(68.7-211.1)	Male	2	6.7	nc	(nc-nc)
Female	7	4.1	171.7	(68.8-353.7)	Female	11	5.8	188.7	(94.0-337.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.3	142.5	(65.0-270.5)
Female	47	47.6	98.8	(72.6-131.4)	Female	7	5.6	124.7	(50.0-257.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	17.3	92.4	(52.8-150.1)	Female	1	5.0	nc	(nc-nc)
Female	17	16.7	102.0	(59.4-163.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.3	nc	(nc-nc)
Male	8	2.9	273.5	(117.7-538.9)	Female	4	3.5	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	47.2	91.2	(66.0-122.8)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.0	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	<u>Testis</u>				
Female	7	3.2	219.2	(87.8-451.6)	Male	4	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	2.1	289.0	(105.5-629.1)	Male	2	1.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	9	5.2	174.2	(79.5-330.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.8	nc	(nc-nc)	Female	7	9.5	73.7	(29.5-151.8)
Female	5	3.2	156.2	(50.3-364.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	159	157.7	100.8	(85.8-117.8)
Male	1	2.4	nc	(nc-nc)	Female	181	153.2	118.1	(101.6-136.7)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	21.6	101.7	(63.7-154.1)					
Female	28	19.9	140.7	(93.5-203.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	18.0	77.7	(42.4-130.3)	Male	9	9.2	97.6	(44.6-185.3)
Female	5	6.3	79.6	(25.6-185.7)	Female	5	7.1	70.5	(22.7-164.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	6	2.7	219.3	(80.1-477.2)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	8.9	78.7	(31.5-162.2)
Female	72	64.5	111.6	(87.3-140.5)	Female	13	8.0	162.2	(86.3-277.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	1	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	27.2	99.2	(65.4-144.3)	Female	10	6.8	147.3	(70.5-270.9)
Female	29	25.8	112.3	(75.2-161.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.2	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	Female	2	5.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	87	73.1	119.0	(95.3-146.8)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.7	nc	(nc-nc)
Male	3	7.3	nc	(nc-nc)	<u>Testis</u>				
Female	4	4.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.1	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	5.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.4	nc	(nc-nc)	Female	12	13.2	91.2	(47.1-159.4)
Female	2	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	207	237.8	87.1	(75.6-99.8)
Male	2	3.4	nc	(nc-nc)	Female	204	215.0	94.9	(82.3-108.8)
Female	3	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	34.4	58.1	(35.5-89.7)					
Female	16	29.9	53.5	(30.6-86.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	2.9	171.9	(55.4-401.1)	Male	2	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	4	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	19	10.8	176.3	(106.1-275.4)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	4.4	247.2	(123.2-442.4)	Female	0	1.1	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.8	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	11.6	120.4	(65.8-202.1)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	54	38.8	139.1	(104.5-181.4)
Male	1	0.6	nc	(nc-nc)	Female	33	33.8	97.5	(67.1-137.0)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	5.5	91.2	(29.4-212.9)					
Female	1	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.1	98.7	(49.2-176.6)	Male	1	5.2	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	54	39.7	135.9	(102.1-177.3)	Female	5	5.7	88.0	(28.4-205.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	16.5	72.9	(37.6-127.3)	Female	2	4.4	nc	(nc-nc)
Female	21	20.0	105.0	(65.0-160.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.1	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	66	40.9	161.2	(124.7-205.1)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	6	2.8	211.7	(77.3-460.8)
<u>Kidney & Renal Pelvis</u>					Female	2	2.2	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.3	184.5	(67.4-401.6)	Female	9	8.1	111.3	(50.8-211.2)
Female	5	3.2	154.4	(49.8-360.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	133	138.6	96.0	(80.4-113.8)
Male	0	1.9	nc	(nc-nc)	Female	144	145.3	99.1	(83.6-116.7)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	20.2	44.6	(20.4-84.7)					
Female	16	20.5	78.2	(44.7-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	18.7	91.0	(53.0-145.7)	Male	11	11.1	99.4	(49.6-177.9)
Female	5	6.8	74.0	(23.8-172.7)	Female	10	9.2	108.1	(51.8-198.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.1	145.3	(53.1-316.3)	Male	1	2.8	nc	(nc-nc)
Female	5	3.5	142.7	(46.0-333.1)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.4	77.2	(33.3-152.2)
Female	82	77.0	106.5	(84.7-132.2)	Female	9	9.1	98.7	(45.0-187.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	8	7.9	101.0	(43.5-198.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	28.9	93.5	(61.6-136.1)	Female	12	8.0	149.6	(77.2-261.3)
Female	24	27.4	87.6	(56.1-130.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.5	91.2	(29.4-212.9)
Male	6	4.9	122.1	(44.6-265.8)	Female	4	5.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	80.7	112.8	(90.8-138.5)
Male	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.5	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	8	8.5	94.4	(40.6-186.0)	<u>Testis</u>				
Female	3	5.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	12	8.0	150.1	(77.4-262.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.3	94.7	(34.6-206.1)	Female	14	15.5	90.3	(49.3-151.4)
Female	8	5.2	153.1	(65.9-301.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	273	264.3	103.3	(91.4-116.3)
Male	4	3.9	nc	(nc-nc)	Female	271	249.1	108.8	(96.2-122.5)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	36.7	114.6	(82.6-154.9)					
Female	50	32.9	152.1	(112.9-200.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.3	83.9	(33.6-172.9)	Male	2	4.9	nc	(nc-nc)
Female	5	3.0	168.9	(54.4-394.2)	Female	3	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	26	32.7	79.6	(52.0-116.6)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.6	nc	(nc-nc)	Male	7	3.4	204.4	(81.9-421.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	12.8	117.0	(65.4-192.9)	Female	8	3.4	232.6	(100.1-458.3)
Female	13	12.1	107.4	(57.1-183.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.4	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	34.7	95.1	(65.4-133.6)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.8	177.5	(57.2-414.3)	Female	5	6.5	76.5	(24.6-178.5)
Female	2	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	109	115.7	94.2	(77.3-113.6)
Male	2	1.7	nc	(nc-nc)	Female	109	107.6	101.3	(83.2-122.2)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	16.0	99.7	(57.0-161.9)					
Female	25	14.3	174.7	(113.0-257.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.4	87.2	(55.3-130.9)	Male	20	13.5	148.0	(90.4-228.6)
Female	8	10.2	78.4	(33.7-154.4)	Female	14	11.2	124.8	(68.2-209.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	4.6	215.5	(103.2-396.3)	Male	4	3.8	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	12	13.0	92.4	(47.7-161.3)
Female	109	100.2	108.8	(89.3-131.3)	Female	13	12.9	100.9	(53.7-172.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.2	nc	(nc-nc)	Male	5	9.7	51.8	(16.7-120.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	39.7	68.0	(44.8-99.0)	Female	10	10.7	93.5	(44.8-172.0)
Female	42	43.0	97.7	(70.4-132.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.5	79.9	(29.2-173.9)
Male	3	6.5	nc	(nc-nc)	Female	6	9.0	66.6	(24.3-144.9)
Female	3	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	129	105.4	122.4	(102.2-145.5)
Male	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	6.7	89.4	(32.7-194.7)
<u>Kidney & Renal Pelvis</u>					Female	5	4.6	107.6	(34.7-251.1)
Male	12	10.6	113.0	(58.3-197.4)	<u>Testis</u>				
Female	7	7.2	97.6	(39.1-201.1)	Male	2	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.5	nc	(nc-nc)	Male	8	2.5	314.6	(135.5-619.9)
Female	0	1.3	nc	(nc-nc)	Female	8	8.4	95.5	(41.1-188.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	8.0	75.2	(27.5-163.7)	Female	25	20.3	123.4	(79.8-182.2)
Female	6	7.3	81.9	(29.9-178.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	342	345.6	99.0	(88.7-110.0)
Male	3	4.9	nc	(nc-nc)	Female	325	342.1	95.0	(84.9-105.9)
Female	0	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	39	49.7	78.4	(55.8-107.2)					
Female	32	46.7	68.5	(46.8-96.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female				
<u>Hodgkin Lymphoma</u>					Female				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female				
<u>Larynx</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					Female				
Male	0	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
					Male	7	12.8	54.6	(21.9-112.6)
					Female	7	10.6	65.8	(26.4-135.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	21.9	114.1	(73.8-168.5)	Male	14	11.5	122.1	(66.7-204.9)
Female	7	8.6	81.3	(32.6-167.6)	Female	11	9.8	111.8	(55.7-200.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.9	128.0	(41.2-298.7)	Male	3	3.2	nc	(nc-nc)
Female	6	3.7	162.4	(59.3-353.5)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	6	11.0	54.4	(19.9-118.5)
Female	85	84.7	100.4	(80.2-124.1)	Female	12	11.0	109.0	(56.2-190.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	6	8.0	74.9	(27.4-163.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	33.0	121.1	(86.5-164.9)	Female	14	9.1	154.6	(84.4-259.4)
Female	51	35.9	142.2	(105.9-187.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	6.2	112.2	(45.0-231.2)
Male	3	5.3	nc	(nc-nc)	Female	7	7.6	92.4	(37.0-190.4)
Female	0	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	86.0	115.1	(93.5-140.1)
Male	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.8	nc	(nc-nc)
Male	16	8.8	182.1	(104.0-295.7)	<u>Testis</u>				
Female	7	6.1	114.6	(45.9-236.2)	Male	3	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	7	7.6	92.0	(36.8-189.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.6	120.3	(51.8-237.1)	Female	20	17.1	117.3	(71.6-181.2)
Female	7	6.1	114.9	(46.0-236.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	308	287.0	107.3	(95.7-120.0)
Male	5	4.1	122.8	(39.6-286.5)	Female	324	290.1	111.7	(99.8-124.5)
Female	2	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	41.1	102.3	(73.7-138.2)					
Female	54	40.1	134.6	(101.1-175.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	41.4	77.3	(52.8-109.1)	Male	33	22.2	148.5	(102.2-208.5)
Female	20	15.5	129.4	(79.0-199.9)	Female	16	18.4	86.7	(49.6-140.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.8	90.1	(36.1-185.7)	Male	7	6.0	117.0	(46.9-241.1)
Female	8	6.9	115.3	(49.7-227.3)	Female	5	5.0	99.3	(32.0-231.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	24	21.3	112.9	(72.3-167.9)
Female	168	156.7	107.2	(91.6-124.7)	Female	21	20.0	105.1	(65.1-160.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	7.0	115.0	(49.5-226.6)	Male	16	15.3	104.4	(59.6-169.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	58	62.4	92.9	(70.6-120.1)	Female	14	16.6	84.3	(46.0-141.4)
Female	63	62.4	100.9	(77.5-129.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	11.8	127.6	(71.4-210.5)
Male	9	10.3	87.7	(40.0-166.6)	Female	17	13.3	127.5	(74.2-204.1)
Female	2	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	139	169.5	82.0	(69.0-96.8)
Male	6	3.5	173.0	(63.2-376.5)	<u>Stomach</u>				
Female	4	2.9	nc	(nc-nc)	Male	10	10.5	95.6	(45.8-175.9)
<u>Kidney & Renal Pelvis</u>					Female	6	6.5	91.9	(33.5-199.9)
Male	18	17.1	105.5	(62.5-166.8)	<u>Testis</u>				
Female	7	11.3	62.1	(24.9-127.9)	Male	5	6.5	76.8	(24.7-179.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	7.2	nc	(nc-nc)	Male	9	4.6	197.5	(90.1-375.0)
Female	1	2.1	nc	(nc-nc)	Female	18	14.7	122.5	(72.6-193.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	12.9	116.0	(64.9-191.4)	Female	34	32.0	106.4	(73.6-148.6)
Female	14	11.0	127.7	(69.7-214.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	515	555.8	92.7	(84.8-101.0)
Male	7	7.9	88.7	(35.5-182.7)	Female	571	529.9	107.8	(99.1-117.0)
Female	2	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	76	79.8	95.3	(75.1-119.3)					
Female	84	74.5	112.8	(89.9-139.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	159	174.4	91.2	(77.5-106.5)	Male	53	90.8	58.4	(43.7-76.3)
Female	65	69.0	94.1	(72.7-120.0)	Female	46	78.8	58.4	(42.7-77.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	32.8	54.9	(32.5-86.8)	Male	22	24.9	88.5	(55.5-134.0)
Female	29	30.8	94.1	(63.0-135.1)	Female	23	22.5	102.3	(64.9-153.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	5.3	95.0	(30.6-221.8)	Male	97	88.7	109.4	(88.7-133.5)
Female	537	657.7	81.6	(74.9-88.9)	Female	92	88.7	103.7	(83.6-127.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	36	28.9	124.6	(87.2-172.5)	Male	60	61.0	98.4	(75.1-126.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	237	261.0	90.8	(79.6-103.1)	Female	69	71.5	96.5	(75.1-122.2)
Female	277	289.7	95.6	(84.7-107.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	37	41.4	89.4	(63.0-123.3)	Male	58	49.0	118.4	(89.9-153.1)
Female	13	13.7	94.9	(50.5-162.3)	Female	63	61.1	103.0	(79.2-131.8)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	8	15.6	51.3	(22.1-101.1)	Male	31	44.5	69.7	(47.3-98.9)
Female	13	14.2	91.7	(48.8-156.8)	Female	33	31.2	105.9	(72.9-148.7)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	63	68.0	92.6	(71.2-118.5)	Male	29	28.0	103.5	(69.3-148.7)
Female	55	48.6	113.2	(85.3-147.4)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	28	28.4	98.6	(65.5-142.5)	Female	145	131.7	110.1	(92.9-129.5)
Female	11	8.4	131.5	(65.6-235.3)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	61	55.3	110.3	(84.4-141.7)	Male	39	31.5	123.7	(87.9-169.1)
Female	43	50.9	84.4	(61.1-113.7)	Female	13	13.9	93.4	(49.7-159.8)
<u>Lung and Bronchus</u>					<u>Lung and Bronchus</u>				
Male	332	322.0	103.1	(92.3-114.8)	Male	332	322.0	103.1	(92.3-114.8)
Female	279	318.3	87.6	(77.7-98.6)	Female	279	318.3	87.6	(77.7-98.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	1.5	340.3	(109.7-794.1)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	3	5.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	6.2	227.6	(124.3-381.8)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	25	20.1	124.2	(80.4-183.4)
Male	0	0.3	nc	(nc-nc)	Female	6	16.4	36.5	(13.3-79.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	2.8	nc	(nc-nc)					
Female	0	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.4	84.8	(36.5-167.1)	Male	12	5.7	211.9	(109.3-370.1)
Female	8	3.7	213.5	(91.9-420.8)	Female	5	4.8	104.3	(33.6-243.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.3	170.7	(77.9-324.0)
Female	35	40.9	85.7	(59.7-119.2)	Female	3	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	14.7	109.0	(62.2-177.0)	Female	6	4.3	140.0	(51.1-304.7)
Female	13	15.9	81.8	(43.5-139.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.8	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	38.6	85.4	(58.8-120.0)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.8	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	6	4.0	148.6	(54.3-323.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.2	nc	(nc-nc)	Female	10	7.9	126.5	(60.6-232.7)
Female	3	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	142	131.0	108.4	(91.3-127.7)
Male	0	2.0	nc	(nc-nc)	Female	118	134.2	87.9	(72.8-105.3)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	17.9	100.6	(59.6-159.1)					
Female	10	17.2	58.1	(27.8-106.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	69	51.9	133.1	(103.5-168.4)	Male	45	22.4	201.2	(146.8-269.3)
Female	19	18.7	101.8	(61.3-159.0)	Female	26	16.8	154.9	(101.1-226.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.0	143.8	(68.8-264.5)	Male	4	7.1	nc	(nc-nc)
Female	6	6.6	90.6	(33.1-197.2)	Female	4	6.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.5	nc	(nc-nc)	Male	23	22.6	101.8	(64.5-152.8)
Female	171	157.0	108.9	(93.2-126.5)	Female	26	22.4	116.2	(75.9-170.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.6	89.4	(28.8-208.7)	Male	12	15.2	79.0	(40.8-138.0)
					Female	9	8.5	106.2	(48.4-201.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	69	75.4	91.5	(71.2-115.8)	Female	20	17.2	116.3	(71.0-179.6)
Female	81	77.8	104.0	(82.6-129.3)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.6	120.8	(66.0-202.7)	Male	11	14.1	77.8	(38.8-139.2)
Female	6	3.7	161.7	(59.0-351.9)	Female	20	16.7	120.1	(73.3-185.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	219.9	(70.9-513.3)	Male	249	187.2	133.0	(117.0-150.6)
Female	3	2.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	18	17.9	100.8	(59.7-159.3)	Male	17	12.8	132.3	(77.0-211.9)
Female	15	12.3	121.9	(68.2-201.1)	Female	5	8.3	59.9	(19.3-139.9)
<u>Larynx</u>					<u>Testis</u>				
Male	9	7.8	115.4	(52.6-219.0)	Male	2	3.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	14	14.0	99.8	(54.5-167.4)	Male	0	3.4	nc	(nc-nc)
Female	14	12.2	114.8	(62.7-192.6)	Female	4	10.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	8.2	73.4	(26.8-159.8)	Female	37	32.5	114.0	(80.2-157.1)
Female	1	3.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	104	93.8	110.9	(90.6-134.4)	Male	733	622.3	117.8	(109.4-126.6)
Female	98	85.2	115.0	(93.4-140.2)	Female	616	572.1	107.7	(99.3-116.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;